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Abstract
Cerebral cavernous malformations (CCM) are prevalent vascular malformations
occurring in familial autosomal dominantly inherited or isolated forms. Once
CCM are diagnosed by magnetic resonance imaging, the indication for genetic
testing requires either a positive family history of cavernous lesions or clinical
symptoms such as chronic headaches, epilepsy, neurological deficits, and
hemorrhagic stroke or the occurrence of multiple lesions in an isolated case.
Following these inclusion criteria, the mutation detection rates in a consecutive
series of 105 probands were 87% for familial and 57% for isolated cases.
Thirty-one novel mutations were identified with a slight shift towards propor-
tionally more CCM3 mutations carriers than previously published (CCM1:
60%, CCM2: 18%, CCM3: 22%). In-frame deletions and exonic missense vari-
ants requiring functional analyses to establish their pathogenicity were rare: An
in-frame deletion within the C-terminal FERM domain of CCM1 resulted in
decreased protein expression and impaired binding to the transmembrane
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protein heart of glass (HEG1). Notably, 20% of index cases carrying a CCM
mutation were below age 10 and 33% below age 18 when referred for genetic
testing. Since fulminant disease courses during the first years of life were
observed in CCM1 and CCM3 mutation carriers, predictive testing of minor
siblings became an issue.
Introduction
Cerebral cavernous malformations (CCM; MIM 116860,
603284, 603285) are autosomal dominantly inherited
vascular malformations mainly caused by unambiguously
pathogenic heterozygous loss-of-function mutations in
one of three genes, CCM1, CCM2 or CCM3. In 2008,
we had presented a first follow-up on 28 probands
affected with CCM (Stahl et al. 2008). The mutation
detection rates had been extremely high, being 94% for
familial CCM and 60% for isolated CCM. Since 2005,
inclusion criteria for diagnostic genetic testing have
either been a positive family history or the occurrence
of multiple lesions in an isolated case. Of note, our
molecular genetic testing had been based on direct
sequencing of CCM1, CCM2, and CCM3, quantitative
analyses to detect larger CCM1-3 deletions/duplications
using multiplex ligation-dependent probe amplifications
(MLPA), and – when required – transcript, protein
expression, and interaction analyses from the very begin-
ning onwards.
We here present a consecutive series of 77 further
index cases analyzed since 2009 and highlight that the
proportion of children and adolescents under the age
of 18 presenting as index cases is higher than previ-
ously thought (Gunel et al. 1996; Siegel et al. 2005). In
our cohort, one-third of index patients that were
shown to carry a heterozygous mutation in either
CCM1, CCM2 or CCM3 are children or adolescents.
Since fulminant courses of the disease have only rarely
been reported in infants affected with CCM (Ng et al.
2006; S€ur€uc€u et al. 2006; Gianfrancesco et al. 2007), we
describe two CCM1 mutation carriers who presented
with hemiparesis during their second and third year of
life requiring immediate surgical intervention. One indi-
vidual’s younger sibling had predictive genetic testing
several years later.
Materials and Methods
Genetic testing
Genotype-phenotype analyses of individuals affected with
CCM were approved by local ethics committees (University
of W€urzburg, Study 21/05, University Medicine Greifswald,
No. BB 94/11a) and performed with informed consent.
Genomic DNA was extracted from peripheral blood leuko-
cytes and all coding CCM1-3 exons and adjacent splice sites
were directly sequenced on an ABI 3130xl automated
sequencer (Applied Biosystems, Life Technologies GmbH,
Darmstadt, Germany) and analyzed with SeqPilot software
(JSI medical systems GmbH, Kippenheim, Germany).
Mutation-negative individuals were subsequently screened
for large CCM1-3 alterations using SALSA MLPA Kits
P130 & P131 (MRC Holland, Amsterdam, Netherlands)
(Gaetzner et al. 2007). GenBank and Ensembl accession
numbers are as follows: CCM1 (GenBank: NM_194456.1,
Ensembl: ENST00000394507; numbering of coding
exons 5-20), CCM2 (GenBank: NM_031443.3, Ensembl:
ENST00000258781), and CCM3 (GenBank: NM_145860.1,
Ensembl: ENST00000392750; numbering of coding exons
4-10). Sequences were analyzed in SeqPilot with the En-
sembl datasets. DNA mutation numbering is based on
cDNA sequence with +1 corresponding to the A of the
ATG translation initiation codon. In silico analyses to pre-
dict the pathogenicity of unclassified variants were per-
formed using MutationTaster (http://www.mutationtaster.
org/), MutPred (http://mutpred.mutdb.org/), PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/), and SIFT (http://
sift.jcvi.org/www/SIFT_enst_submit.html) for the exonic
missense and small in-frame mutations and BDGP (http://
www.fruitfly.org/seq_tools/splice.html), Human Splicing
Finder (http://www.umd.be/HSF/), and NetGene2 (http://
www.cbs.dtu.dk/services/NetGene2/) for mutations affect-
ing splice sites and c.313G>C.
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Transcript analyses
In order to analyze the effects of the CCM1:c.2025+1G>A
splice site mutation, RNA was extracted from untreated
peripheral blood leukocytes using the PAXgene Blood
RNA kit (PreAnalytiX, Qiagen, Hilden, Germany). cDNA
was synthesized using SuperScriptTM III Reverse Transcrip-
tase (Invitrogen, Life Technologies GmbH, Darmstadt,
Germany). The region around the presumed skipping of
exon 18 of CCM1 was amplified using a cDNA-specific
forward primer complementary to the exon 16/exon 17
junction (5′-AGCAAGGTTTCCTAAATGAAG-3′) and a
specific reverse primer complementary to the exon 19/
exon 20 junction (5′-CGAGACCAGCCTGTTTTGTA-3′).
PCR products were size-separated by agarose gel electro-
phoresis prior to TOPO TA-Cloning (Invitrogen) and
sequencing.
Generation of plasmids
The human full-length FLAG-tagged CCM1 (FLAG-
CCM1) construct used for transient expression in
HEK293 cells has been described previously (Stahl et al.
2008). To generate FLAG-CCM1:p.N607_K675del, the
altered coding sequence of CCM1 lacking human exon 18
(CCM1:c.2025+1G>A, CCM1:p.N607_K675del) was simi-
larly fused to a FLAG tag, PCR-cloned into the pCR2.1
vector and subcloned into pcDNA3.1(+) vector. The plas-
mid pRc/CMV2-EGFP served as positive control for
transfections and as negative control for western blots.
Protein expression and HEG1-binding assay
HEK293A cells were cultured in DMEM (MediaTek)
supplemented with 10% FBS (Sigma, Saint Louis, MO),
L-glutamine, nonessential amino acids, and penicillin/
streptomycin (all from Invitrogen). Cells were transfected
with Lipofectamine Plus (Invitrogen) reagent following
the manufacturer’s protocol. Twenty-four hours after
transfection, cells were washed twice with ice-cold PBS
and lysed in ice-cold lysis buffer (50 mmol/L Tris-HCL
pH 7.4, 150 mmol/L NaCl, 0.5% NP-40, 5 mmol/L
MgCl2) with freshly supplemented EDTA-free protease
inhibitors (Roche, Mannheim, Germany). Cell lysates
were cleared by centrifuging at 20,000g for 15 min at 4°C.
An aliquot of supernatant was boiled in SDS-PAGE sam-
ple buffer and resolved by SDS-PAGE. After transferring
onto a nitrocellulose membrane, western blot was per-
formed using mouse anti-FLAG M2 antibody (Sigma) to
determine the FLAG-tagged CCM1 protein expressions.
The final lysate volumes were adjusted to level the
expression of FLAG-CCM1 wild-type and mutant pro-
teins. Recombinant biotinylated HEG1 and integrin aIIb
cytoplasmic tail protein production was described previ-
ously (Kleaveland et al. 2009). ELISA plates were coated
with 50 lL of 10 lg/mL neutravidin (Thermo, Schwerte,
Germany) for overnight, blocked with 1% BSA (Sigma)
and then incubated with 2 lg/mL HEG1 tail protein or
aIIb tail protein, respectively. After washing three times
with wash buffer (0.2% Triton X-100, 19 PBS), plates
were incubated with cell lysates accordingly. After wash-
ing, the plates were incubated with mouse anti-FLAG M2
antibody (Sigma) and subsequently rabbit anti-mouse IgG
HRP-conjugated antibody (Thermo). The plates were
developed with chemiluminescence reagent (Thermo) and
read using Victor 2 plate reader (PerkinElmer, Waltham,
MA). Data were analyzed in Graphpad Prizm software.
Results
Summarizing the data published by Stahl et al. (2008; 28
probands divided into 23 mutation carriers and five
mutation-negative individuals, see Table S1) and those
derived from the current series of 77 further probands
(Table 1; including 56 mutation carriers, two unclassified
variants and 19 mutation-negative individuals), 79 of the
105 index cases were found to carry a heterozygous muta-
tion in either the CCM1, the CCM2 or the CCM3 gene.
60% of mutations were found in the CCM1 gene
(n = 48), 18% in CCM2 (n = 14), and 22% in CCM3
(n = 17). 32% (n = 25) of index cases had a stop muta-
tion, 34% (n = 27) a frameshift mutation, 28% (n = 22)
a splice site mutation, affecting or located next to a con-
sensus AG/GT splice site and predicted to result in a
frameshift, and 4% (n = 3) a large genomic deletion. In
two cases (2%), a splice site mutation resulted in single
exon in-frame deletions of CCM1 exon 18 and CCM1
exon 19, respectively. A three base pair in-frame deletion
within CCM1 in an isolated case and an exonic CCM1
missense mutation were categorized as unclassified vari-
ants (UV) and are highlighted by bold letters in Table 1.
In its last column, Table 1 also demonstrates that one-
third of index cases carrying a CCM mutation were below
age 18 when referred for genetic testing.
Case report of a 1-year-old CCM1 mutation
carrier and predictive testing of his infant
sister
As an example for fulminant disease courses in infants,
we here depict in more detail an index case that had
experienced progressive right-sided hemiparesis at the age
of 18 months prior to resection of a hemorrhaging caver-
noma in the left cerebral hemisphere. At that time, a fur-
ther larger cavernoma had been observed in the right
frontal lobe, which increased in size and was electively
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Table 1. CCM1–3 mutations and UVs in the current series of 77 consecutive, unrelated probands.
Gene Exon1 Nucleotide exchange
Predicted amino
acid change Presentation2 Reference
Age at referral
to genetic
testing
CCM1 6 c.143dupA p.R49Efs*15 f Cave-Riant et al. (2002) 51
7 c.313G>C p.G105R f Novel 12
8 c.406C>T p.Q136* f Novel 46
9 c.557dupT p.T188Nfs*2 f Novel 1
IVS9 c.729+5G>A p.Q201Rfs*23 f Novel 44
IVS9 c.730-1G>A p.? i Davenport et al. (2001) 27
10 c.842delA p.D281Afs*7 f Novel 28
IVS10 c.845+1G>A p.? i Novel 36
IVS10 c.845+1G>T p.? f Novel 77
11 c.877delC p.H293Tfs*12 f Novel 15
12 c.1093G>T p.G365* f Novel 1
13 c.1166delG p.G389Efs*5 f Novel 71
13 c.1197_1199delCAA p.N399del f Novel 44
IVS13 c.1255-1G>A p.Y419Ffs*153 f Cave-Riant et al. (2002) 31
14 c.1255_1270delTATGAAAAAGTTCGAA p.E420Tfs*12 f Novel 78
14 c.1267C>T4 p.R423* i/f Cave-Riant et al. (2002) 23,63,79,44,32
14 c.1306_1310delTTGAA p.L436Afs*4 f Battistini et al. (2007) 7
IVS14 c.1412-1G>C p.? i Novel 26
15 c.1431T>A p.Y477* i Novel 24
15 c.1531delG p.D511Mfs*2 i Novel 23
IVS15 c.1564-1G>A p.? f Novel 32
16 c.1619T>A p.L540* f Novel 10
16 c.1660_1678delTTGGCAAGTCTGCTTTTGC p.L554Kfs*2 i Novel 14
16 c.1678C>T p.Q560* f Stahl et al. (2008) 8
IVS16 c.1730+4_1730+7delAGTA4 p.I522*3 f Cave-Riant et al. (2002) 51,17
17 c.1806_1807insAT p.H603Ifs*59 i Novel 31
18 c.1950dupC p.S651Qfs*4 f Novel 13
18 c.1961_1962delAA p.K654Sfs*21 f Novel 43
IVS18 c.2025+1G>A p.N607_K675del3 f Denier et al. (2004) 21
IVS18 c.2026-12A>G p.A676_Q714del3 f Laberge-le Couteulx et al.
(1999), Cave-Riant et al.
(2002)
5
Deletion of entire CCM1 gene f Gaetzner et al. (2007) 51
CCM2 1 c.1-36_4del, 40 bp deletion including
start codon
p.? i Novel 35
1 c.30G>A4 No transcript i/f Liquori et al. (2003) 16,71
IVS2 c.205-2_205-1delAGinsT p.Y69Vfs*33 f Stahl et al. (2008) 43
10 c.1071_1074dupCCCT p.E359Pfs*2 f Novel 47
10 c.1255dupG p.D419Gfs*2 f Novel 33
CCM3 4 c.63_64dupCC p.L22Pfs*13 f Novel 42
5 c.103C>T4 p.R35* i/f Bergametti et al. (2005) 8,11,20,1
5 c.113delT p.L38Rfs*7 f Novel 53
IVS6 c.269-1G>T p.? f Novel 3
7 c.317delA p.K106Rfs*20 i Novel 2
7 c.334_337delCAAA p.Q112Ffs*13 f Novel 20
7 c.391delA p.I131Sfs*4 f Novel 1
IVS8 c.475-2A>G p.A119Gfs*423 i Novel 22
IVS9 c.558-1G>C4 p.? i/f Novel 11,36
IVS9 c.558-2A>C p.? i Novel 3
10 c.586C>T p.R196* i Bergametti et al. (2005) 17
10 c.598C>T p.Q200* f Schr€oder et al. (2014) 50
UVs are depicted in bold letters. The 19 mutation-negative index cases of this cohort are not included.
1Exon numbering according to Ensembl CCM1 transcript NM_194456.1 (coding Exons 5-20), CCM2 transcript NM_031443.3 and CCM3 transcript
NM_145860.1 (coding Exons 4–10).
2Presentation: f, familial; i, isolated.
3Confirmed by transcript analysis.
4Was observed in two or more independent families as judged by family history, ages are given for all index patients.
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resected at the age of 2 years and 4 months (Fig. 1A). In
addition, the boy revealed multiple further silent caverno-
mas (Fig. 1B) and a vascular retinal malformation. At the
age of 3½ years, mild residual hemiparesis primarily of
the right leg was documented, while yearly MRI demon-
strated stable cavernomatosis until the age of currently
8 years. The proband was already listed in the cohort
from Stahl et al. 2008 and is heterozygous for the CCM1
gene mutation c.1255-4_1255-2delGTA, which is pre-
dicted to destroy the splice acceptor site of exon 14 and
to result in a truncated protein. This mutation had also
been reported to segregate in a three-generation pedigree
(Verlaan et al. 2002).
The proband’s father reported that he had experienced
headaches in his childhood, but has been asymptomatic
thereafter. The parents are first degree cousins and both
parents decided to be genetically tested and actively asked
for predictive testing of their younger daughter when she
was 3 years and 8 months old. Only the father, but not
his daughter turned out to carry his son’s mutation, but
thus far has not decided to ask for neuroimaging.
Functional characterization of a single exon
in-frame deletion within the FERM domain
of CCM1: decreased protein expression and
loss of binding to HEG1
Previously, a genomic deletion involving CCM2 exon 2
had been shown to lead to an in-frame deletion of 58
amino acids resulting in impaired binding of CCM2:
p.P11_K68del to CCM1 and the inability to form a
CCM1/CCM2:p.P11_K68del/CCM3 complex in vitro
(Stahl et al. 2008). An in-frame deletion of 18 amino
acids encoded by CCM3 exon 5 (CCM3:p.L33_K50del)
had been reported to result in loss of CCM3:
p.L33_K50del binding to serine/threonine protein kinases
STK25 and MST4 (Voss et al. 2009). Therefore, we
intended to elucidate the mechanisms of action of CCM1:
p.N607_K675del identified in this study.
The mutation c.2025+1G>A within CCM1 (CCM1:
p.N607_K675del) was found in a 21-year-old female who
reported to have experienced sudden right-sided hemipa-
resis at the age of 2 years. A large cavernoma in the left
basal ganglia had only been partially removed and her
right-sided hemiparesis persisted. Her mother suffered
from drug-resistant epilepsy due to multiple cavernomas
since the age of 42 and underwent surgical resection of
two temporal cavernomas at the age of 46 (Fig. 2A). She
also turned out to be a heterozygous carrier of CCM1:
c.2025+1G>A (Fig. 2B and C).
CCM1:c.2025+1G>A affects a canonical splice site and
is predicted to lead to an in-frame deletion of exon 18
(Fig. 2D). Screening of the entire CCM1, CCM2, and
CCM3 genes by direct sequencing and MLPA did not
demonstrate a further pathogenic mutation in this pro-
band. Consequently, cDNA analyses were performed dem-
onstrating aberrant splicing of exon 18 resulting in a
CCM1 transcript lacking exon 18 (Fig. 2E and F). CCM1
Exons 14 to 20 encode for the C-terminal FERM domain
of the CCM1/KRIT1 protein. Numerous mutations of all
types have been reported to cluster within this region. In
particular, independent transcript analyses have shown
that the splice site mutation CCM1:c.2026-12A>G results
in the deletion of entire exon 19, which encodes 39
amino acids (CCM1:p.A676_Q714del) (Table 1 and
Laberge-le Couteulx et al. 1999; Cave-Riant et al. 2002;
Riant et al. 2013b).
CCM1:c.2025+1G>A is predicted to cause a 69 amino
acid deletion (CCM1:p.N607_K675del), which resides
within the C-terminal FERM domain of the CCM1/KRIT1
protein that has been shown to interact with several pro-
teins including RAS-related protein RAP1, which was
shown to maintain the integrity of endothelial junctions
(Glading et al. 2007). Most recently, the structure of the
complex of CCM1 FERM domains and the C-terminus of
the transmembrane protein heart of glass (HEG1) was
solved (Gingras et al. 2012). As demonstrated in a model
of the FERM domain (Fig. 3A), the N-terminal beta sheet
of the F3 lobe that forms an essential part of the HEG1-
binding site is deleted in CCM1:p.N607_K675del, while
the major RAP1-binding site is spared. In order to investi-
gate whether such a structurally altered protein would be
stable, the expression of recombinant mutant CCM1:
p.N607_K675del protein was analyzed. Recombinant
Figure 1. Characteristic MRI findings in CCM. MRI of a 1-year-old
CCM1 mutation carrier showing coronal (A) T2 and (B) axial T2*w
sequences. (A) There is a huge mulberry-like cavernoma in the right
frontal lobe (white arrowhead). Blood-degradation products of varying
age cause a reticulated signal within the cavernoma. (B) T2*w
imaging reveals multiple hypointense areas corresponding to
hemosiderin depositions of several larger and dot-sized cavernomas
(arrowheads).
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FLAG-tagged CCM1 protein lacking the 69 amino acids
encoded by exon 18 (FLAG-CCM1:p.N607_K675del) was
expressed with significantly reduced efficiency (~20%) in
HEK293 cells when compared to FLAG-tagged CCM1
(Fig. 3B). To analyze whether interaction of CCM1:
p.N607_K675del with HEG1 is abrogated, cell lysates were
adjusted accordingly to make sure that the abundance of
both wild-type and mutant proteins were similar. Capture
ELISA assays revealed that FLAG-CCM1:p.N607_K675del
showed markedly reduced binding to the HEG1 cytoplas-
mic tail when compared to FLAG-tagged CCM1 protein
indicating that loss of exon 18 disrupts the interaction
capacity of CCM1 to HEG1 (Fig. 3C). Thus, the in-frame
deletion of exon 18 within CCM1 fits into the spectrum
of loss-of-function mutations observed for CCM1, CCM2,
and CCM3.
Unclassified variants within CCM1
The small in-frame deletion c.1197_1199delCAA (CCM1:
p.N399del) results in the omission of a conserved aspara-
gine within the ankyrin 4 repeat domain. According to
Mutation Taster and SIFT, this deletion is probably dam-
aging. It was found in a 42-year-old individual who had
been diagnosed as having multiple cavernomas after a
severe attack of headaches. However, this in-frame dele-
tion was inherited from his mother who was asymptom-
atic and had no lesions on MRI at the age of 70 years.
Further in silico analyses revealed no differences in poten-
tial splice sites (HSF, NetGene2, BDGP). Taken together,
c.1197_1199delCAA was classified as UV.
The novel UV c.313G>C within the CCM1 gene was
found in a 12-year-old proband whose family did not
consent to transcript and segregation analyses so far. In
silico analyses suggest that this exonic missense variant
changes a conserved glycine into an arginine (p.G105R)
and is probably damaging (Polyphen2, Mutation Taster,
SIFT, MutPred). According to HSF, the use of an alterna-
tive downstream splice acceptor within exon 7 is also
conceivable. However, CCM1:c.313G>C cannot be consid-
ered to be a disease-causing mutation at this stage. The
patient’s parents have been informed that neuroradio-
logical imaging is currently recommended to those at-risk
family members who want to specify their disease risk.
Discussion
Taken together, mutation detection rates for all 105 index
cases analyzed between 2005 and 2012 are 87% for famil-
ial (n = 55 of 63) and 57% for isolated cases (n = 24 of
42). Thus, they are slightly lower but consistent with the
ones reported previously (Denier et al. 2006; Stahl et al.
2008). Given that Knudson’s two-hit hypothesis has been
confirmed for several hereditary vascular malformations
(Limaye et al. 2009), one explanation of the observed
lower mutation detection rate in isolated cases would be
the postzygotic occurrence of both hits that may remain
undetected in peripheral blood cells with the mutation
scanning techniques applied. Notably, the CCM cohort
Figure 2. Single exon in-frame deletion within the FERM domain of
CCM1. (A) Contrast-enhanced T1-weighted MR showing two left
temporal cavernomas (white arrowheads) causing drug-resistant
epilepsy in a 46-year-old female (upper left panel). Intraoperative view
after resection of the two temporal cavernomas and their surrounding
hemosiderin (upper right panel). Minimal skin incision (lower left
panel). Cosmetic result after 1 week (lower right panel). (B) Pedigree
of the proband’s family. (C and D) Direct sequencing revealed the
splice site mutation c.2025+1G>A within CCM1 likely resulting in
skipping of exon 18. (E) A smaller transcript is visible in the proband.
(F) Electropherogram showing the junction between exon 17 and
exon 19 in the smaller transcript.
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presented in this study was initiated in 2005 in a com-
bined diagnostic and research setting using stringent
inclusion criteria. A recent CCM1-3 gene analysis which
included patients referred for cerebral hemorrhages of
unknown etiology yielded a significantly lower mutation
detection rate of 44% (Riant et al. 2013b).
13% (n = 8) of familial and 43% (n = 18) of isolated
cases of this cohort remain mutation-negative (Fig. 4), if
the two carriers of the unclassified variants (UV, only
2%) are not considered as pathogenic. Although some of
the mutation-negative cases may bear a mutation in regu-
latory regions of the known CCM1-3 genes, this observa-
tion alludes to further genetic heterogeneity in CCM.
However, the identification of novel CCM genes using
trio-based exome sequencing may be hampered by the
above-mentioned postzygotic somatic mosaicism in iso-
lated mutation-negative cases, genetic heterogeneity itself,
and incomplete disease penetrance. Magnetic resonance
imaging of parents from isolated cases revealed that a
large proportion of presumed isolated cases are in fact
unrecognized familiar forms (Labauge et al. 1998). There-
fore, we suggested to the referring physicians that genetic
counseling and molecular as well as neuroradiological
evaluation should be offered to parents and subsequently
to further at-risk family members of all isolated cases with
multiple lesions. Most relatives of individuals categorized
as isolated in this study have not yet decided to pursue
further steps.
Regarding the distribution of CCM1, CCM2, and
CCM3 mutation rates, a slight shift toward proportionally
more CCM3 mutations carriers than previously published
(Stahl et al. 2008) was observed: 60% of mutations were
found in the CCM1 gene (n = 48), 18% in CCM2
(n = 14), and 22% in CCM3 (n = 17). Such a tendency
can also be observed in the French cohorts: CCM3 muta-
tion carriers were found in 13% in 2006, which increased
to 16% and 18% in 2013 (Denier et al. 2006; Riant et al.
2013a,b), the distribution being comparable with the
Figure 3. Single exon in-frame deletion within the FERM domain of CCM1 results in decreased protein expression and abrogates binding to
HEG1. (A) Molecular view of CCM1 FERM domain bound to the HEG1 tail. The HEG1 tail is shown in yellow. The CCM1 FERM domain consists
of three subdomains: F1 (green), F2 (red), and F3 (orange). The deletion in CCM1 encompassing the amino acids encoded by exon 18 is shown in
gray and results in the deletion of structural elements within the FERM subdomains F2 and F3. The model also illustrates that the deletion spares
the RAP1-binding site within CCM1 which is encircled in blue. (B) Western blot analysis of protein lysates. Compared with wild-type 84 kDa
FLAG-CCM1 (lane 1), FLAG-CCM1:p.N607_K675del (FLAG-CCM1Δ) migrated at about 77 kDa (lane 2) and its expression was significantly
reduced to ~20% of the FLAG-CCM1 wildtype, while cotransfected GFP and endogenous RhoDGI levels were not altered. (C) Capture ELISA
assays demonstrate that HEG1-bound significantly reduced amounts of FLAG-CCM1Δ (open bars) when compared to FLAG-CCM1 (black bars).
Cell lysates were adjusted to match the FLAG-CCM1 expression levels.
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cohort presented here: 63% for CCM1, 19% for CCM2,
and 18% for CCM3 (Riant et al. 2013b). Furthermore, it
was suggested in the larger French cohort that CCM3
mutations might be associated with the development of
multiple meningiomas (Riant et al. 2013a): seven unre-
lated CCM3 mutation carriers out of 54 were shown to
have dural-based lesions with typical radiological features
of meningiomas. In line with this observation, two CCM3
mutations were associated with meningiomas in our
group of 17 CCM3 mutation carriers: c.317delA (unpub-
lished data) and c.598C>T (Schr€oder et al. 2014).
Notably, the mean age at referral was 18 years for
index patients with a CCM3 mutation (ranging from 1 to
53 years), while the mean age at referral was 30.5 years
for CCM1 probands (ranging from 1 to 79 years) and
40 years for CCM2 probands (ranging from 16 to
71 years) (Table 1 and Table S1 adding the age at referral
to the probands published by Stahl et al. (2008), see
Table S1).
Since predictive testing of infant at-risk relatives
becomes an issue, we have grouped children and adoles-
cents into two groups, those below age 10 who might
require sedation for MRI and those below age 18. In our
cohort of 79 index patients who harbored a mutation in
CCM1, CCM2, or CCM3, 20% (n = 16) of index cases
were below the age of 10 and 33% (n = 26) of index cases
below the age of 18. CCM1 mutations were identified in
15 probands younger than 18 years (19%) and CCM3
mutations in 10 (13%), while a CCM2 mutation was
observed only once in this age group in our cohort (1%).
Given that the age of disease manifestation (e.g., 2 years
for the proband carrying CCM1:c.2025+1G>A; Fig. 2) has
previously been much earlier than the age at referral to
genetic testing (e.g., 21 years for the same proband), dis-
ease manifestation is likely much earlier than previously
reported.
In the past, it has been referenced that 9% of individu-
als become symptomatic before age 10 (Siegel et al.
2005). However, the original publication (Gunel et al.
1996) referred to by Siegel et al. (2005) was likely biased
toward CCM1 mutation carriers: Among 47 patients
mostly derived from Hispanic American kindreds that
later turned out to carry a nonsense founder mutation in
CCM1 (Sahoo et al. 1999; Zhang et al. 2000), only four
were given a diagnosis before the age of 10. More
recently, mutation carriers have been grouped in two cat-
egories, those with disease manifestation before and after
age 15 (Denier et al. 2006). In this cohort, 20% of
patients became symptomatic before age 15, the propor-
tions being 17% for CCM1, 19% for CCM2, and 50% for
CCM3 (Denier et al. 2006). The proportions of our
patients with an onset below age 15 are 25% for CCM1
(12/48), 0% for CCM2 and 53% for CCM3 (9/17). One
explanation for earlier disease manifestation in CCM3
mutation carriers has been the observation that children
harboring a CCM3 mutation present with significantly
more lesions than those with a CCM1 mutation at a simi-
lar age (Nikoubashman et al. 2013).
Predictive testing of at-risk family members below age
18 was requested and performed in 12 cases after thor-
ough genetic counseling (for further information on
counseling in the context of predictive testing for CCM
see Schr€oder et al. 2014). As demonstrated for the family
of the CCM1:c.1255-4_1255-2delGTA mutation carrier
who had experienced increasing right-sided hemiparesis
at the age of 18 months (Fig. 1A and B), the respective
familial mutation was excluded in eight relatives under
the age of 18 (data not shown), thus relieving these
relatives and their families of unnecessary anxieties and
medical examinations.
Improved neuroimaging methods have led to increased
identification of incidental isolated cavernomas that often
Figure 4. Distribution of mutations of the entire CCM cohort. The data reported by Stahl et al. (2008) are included. Total numbers are given in
brackets. UV, unclassified variant, integrated into the figure as a separate entity.
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remain clinically silent. Similarly, it can be anticipated that
entire CCM gene deletions or small mutations within
known CCM genes will occur as coincidental findings
during diagnostic genome-wide array or next-generation
sequencing analyses of, for example, syndromic neonates
or infants with developmental delay. Better knowledge of
early disease manifestations and courses resulting in guide-
lines on neuropediatric and neuroradiological monitoring
and management of mutation carriers in this age group
will be useful for genetic counseling of their families.
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